Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YY201 in Advanced Solid Tumors and Hematological Malignancies
NCT06225856Phase 1Recruiting
- Sponsor
- Yuyao Biotech
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YY201 in solid tumor (advanced stage), hematological malignancies, lymphoma and 6 more, sponsored by Yuyao Biotech. Primary endpoints: Dose limiting toxicity up to 31 days, Maximum tolerated dose up to 24 months and 2 more. Started Oct 2023; status: recruiting.
02
Drugs
YY201
03
Conditions
solid tumor (advanced stage)hematological malignancieslymphomalarge granular lymphocytic leukemia (LGLL)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06225856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06225856.